Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Altair Therapeutics Reports Successful Completion Of Phase I Study Of Inhaled AIR645
Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, reported results from its phase I study evaluating the safety, tolerability and pharmacokinetics of its lead product, once-weekly inhaled AIR645, in healthy volunteers. AIR645 is a non-steroidal dual inhibitor of cellular responses to interleukin (IL)-4 and IL-13, cytokines that play a critical role in development and progression of asthma, rhinitis and other allergic disorders. Results presented today at the 2009 International Conference of the American Thoracic Society (ATS) within the Mini-Symposium "New Treatment Approaches for Asthma and Allergy" showed that inhaled AIR645 was safe, well tolerated and had dose-dependent exposure in the airways. These results demonstrate the potential of AIR645 as a convenient once-weekly treatment for asthma and other respiratory disorders. Later this year, Altair plans to initiate a phase II efficacy study in patients with asthma.
generic viagra online
Leading Scientists Warn Over Lack Of Dementia Investment
The UK needs a national plan for dementia research or the country will pay the price, the UK"s top scientists are warning today.
News of the day
Green Tea Compound May Block A Key Process In Alzheimer's Development
Researchers affiliated with Natura Therapeutics, Inc., Tampa, Florida, and the University of South Florida (USF) have jointly received a one-year, $110,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health"s (NIH) National Center for Complementary and Alternative Medicine to continue studying TeaMem™, a compound made from green tea.
Mental Health

IFPMA Announces Johnson & Johnson As New Member Company

The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is pleased to announce that Johnson & Johnson has become its newest member company. IFPMA Acting Director General Michael D. Boyd said: "Johnson & Johnson is an important company in our industry and one which is particularly active in working to help improve health in developing countries. The IFPMA is very pleased that Johnson & Johnson has joined; this is good for the IFPMA, and we expect it will benefit Johnson & Johnson, as well." Johnson & Johnson is the world"s most comprehensive healthcare company, with more than 250 companies in 57 countries employing 119,000 people worldwide engaged in the research and development, manufacture and sales of a broad range of health care products, including pharmaceuticals, medical devices and diagnostics. Its worldwide headquarters is in New Brunswick, New Jersey, USA. The company is committed to bringing innovative ideas, products and services to market that advance the health and well-being of people throughout the world. For general information on Johnson & Johnson, please go to http://www.jnj.com. For information on the company"s activities to help improve health in underserved communities, please go to http://www.jnj.com/connect/caring/medicine-access/. IFPMA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009